S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NASDAQ:IDXX

IDEXX Laboratories - IDXX Stock Forecast, Price & News

$420.63
-7.91 (-1.85%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$420.39
▼
$429.59
50-Day Range
$324.64
▼
$441.27
52-Week Range
$317.06
▼
$664.70
Volume
279,601 shs
Average Volume
573,986 shs
Market Capitalization
$34.84 billion
P/E Ratio
53.45
Dividend Yield
N/A
Price Target
$473.13

IDEXX Laboratories MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
12.5% Upside
$473.13 Price Target
Short Interest
Bearish
2.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.76
Upright™ Environmental Score
News Sentiment
0.01mentions of IDEXX Laboratories in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$12.54 M Sold Last Quarter
Proj. Earnings Growth
18.99%
From $7.90 to $9.40 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

299th out of 1,022 stocks

Diagnostic Substances Industry

3rd out of 15 stocks

See Top Rated MarketRank™ Stocks Here
IDXX stock logo

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

December 8, 2022 | americanbankingnews.com
Brokerages Set IDEXX Laboratories, Inc. (NASDAQ:IDXX) Target Price at $473.13
December 7, 2022 | finance.yahoo.com
11 Best Pet Stocks To Buy Now
December 7, 2022 | americanbankingnews.com
Kathy V. Turner Sells 3,000 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock
December 5, 2022 | seekingalpha.com
IDEXX Laboratories: Not Enough Visibility, Hold
November 17, 2022 | benzinga.com
Massive Insider Trade At IDEXX Laboratories
November 15, 2022 | msn.com
Morgan Stanley Maintains Overweight Rating for IDEXX Laboratories: Here's What You Need To Know
November 15, 2022 | forbes.com
Is There More Room For Growth In IDEXX Laboratories Stock?
November 10, 2022 | benzinga.com
IDEXX Laboratories President & CEO Trades Company's Stock
November 10, 2022 | benzinga.com
IDEXX Laboratories Recent Insider Activity
November 8, 2022 | msn.com
Looking Into IDEXX Laboratories's Return On Capital Employed
November 8, 2022 | finance.yahoo.com
IDEXX Laboratories Third Quarter 2022 Earnings: Beats Expectations
November 1, 2022 | msn.com
Why IDEXX Stock Popped Today
November 1, 2022 | seekingalpha.com
IDEXX Laboratories rises on Q3 beat, narrows FY22 outlook on forex impact
November 1, 2022 | nasdaq.com
IDEXX Laboratories Inc Profit Climbs In Q3, Beats estimates
November 1, 2022 | msn.com
Peering Into IDEXX Laboratories's Recent Short Interest
November 1, 2022 | msn.com
Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 10 Years
October 26, 2022 | finance.yahoo.com
Nevro (NVRO) Expected to Beat Earnings Estimates: Should You Buy?
October 26, 2022 | seekingalpha.com
A Quality Checkup On IDEXX Laboratories
October 22, 2022 | seekingalpha.com
IDXX IDEXX Laboratories, Inc.
October 17, 2022 | marketwatch.com
How the price action of Idexx Laboratories (IDXX) is used to our Advantage
October 17, 2022 | markets.businessinsider.com
Expert Ratings for IDEXX Laboratories
October 11, 2022 | finance.yahoo.com
IDEXX Laboratories to Release 2022 Third Quarter Financial Results
October 2, 2022 | finance.yahoo.com
IDEXX Laboratories, Inc. (IDXX)
September 23, 2022 | nasdaq.com
RSI Alert: Idexx Laboratories (IDXX) Now Oversold
September 8, 2022 | forbes.com
Should You Buy IDEXX Laboratories Stock At Around $350?
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Company Calendar

Last Earnings
11/02/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/01/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
CIK
874716
Web
www.idexx.com
Phone
(207) 556-0300
Fax
207-556-4346
Employees
10,350
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$473.13
High Stock Price Forecast
$582.00
Low Stock Price Forecast
$415.00
Forecasted Upside/Downside
+12.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$7.87
Trailing P/E Ratio
53.45
Forward P/E Ratio
53.24
P/E Growth
3.07
Net Income
$744.84 million
Net Margins
20.05%
Pretax Margin
25.11%
Return on Equity
118.38%
Return on Assets
26.06%

Debt

Debt-to-Equity Ratio
1.60
Current Ratio
0.89
Quick Ratio
0.59

Sales & Book Value

Annual Sales
$3.22 billion
Price / Sales
10.83
Cash Flow
$10.03 per share
Price / Cash Flow
41.94
Book Value
$8.14 per share
Price / Book
51.67

Miscellaneous

Outstanding Shares
82,817,000
Free Float
81,111,000
Market Cap
$34.84 billion
Optionable
Optionable
Beta
1.18

Social Links


Key Executives

  • Mr. Jonathan J. MazelskyMr. Jonathan J. Mazelsky (Age 61)
    Pres, CEO & Director
    Comp: $3.07M
  • Mr. Brian P. McKeonMr. Brian P. McKeon (Age 60)
    CFO, Exec. VP & Treasurer
    Comp: $1.43M
  • Mr. James F. PolewaczykMr. James F. Polewaczyk (Age 58)
    Exec. VP & Chief Commercial Officer
    Comp: $1.19M
  • Mr. Michael J. LaneMr. Michael J. Lane (Age 54)
    Exec. VP and GM of Reference Laboratories & Information Technology
    Comp: $1.19M
  • Dr. Nimrata Khatra Hunt P.E. (Age 54)
    Ph.D., Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations
    Comp: $1.18M
  • Mr. John Hart
    Sr. VP of Worldwide Operations
  • Mr. Jeffery D. Chadbourne (Age 46)
    Sr. Director of Accounting & Financial Reporting
  • Dr. Martin Smith Ph.D. (Age 54)
    Exec. VP & CTO
  • Mr. Ken Grady
    Sr. VP & Chief Information Officer
  • Ms. Sharon E. Underberg (Age 61)
    Exec. VP, Gen. Counsel, & Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













IDXX Stock - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings or view top-rated stocks.

What is IDEXX Laboratories' stock price forecast for 2023?

9 Wall Street research analysts have issued twelve-month price objectives for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $582.00. On average, they predict the company's share price to reach $473.13 in the next year. This suggests a possible upside of 12.5% from the stock's current price.
View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2022?

IDEXX Laboratories' stock was trading at $658.46 at the start of the year. Since then, IDXX shares have decreased by 36.1% and is now trading at $420.63.
View the best growth stocks for 2022 here.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 1st 2023.
View our IDXX earnings forecast.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its earnings results on Tuesday, November, 2nd. The company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.15. The business had revenue of $810.42 million for the quarter, compared to analysts' expectations of $793.26 million. IDEXX Laboratories had a trailing twelve-month return on equity of 118.38% and a net margin of 20.05%. During the same quarter last year, the business earned $1.69 earnings per share.
Read the conference call transcript.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of $7.74-$7.98 for the period, compared to the consensus EPS estimate of $7.95. The company issued revenue guidance of $3.33 billion-$3.37 billion, compared to the consensus revenue estimate of $3.37 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.62%), Vanguard Group Inc. (9.72%), State Street Corp (4.57%), Alliancebernstein L.P. (3.51%), Blair William & Co. IL (1.48%) and Brown Advisory Inc. (1.46%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $420.63.

How much money does IDEXX Laboratories make?

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $34.84 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $7.87 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

The company employs 10,350 workers across the globe.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 12/9/2022 by MarketBeat.com Staff